LOVELACE BIOMEDICAL RESEARCH INSTITUTE

EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES.

RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP])

SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP).

TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA

BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES

ANNUAL SOFTWARE LICENSE/MAINTENANCE AGREEMENT FOR THE ANIMAL MANAGEMENT SYSTEM.

STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS.

TRANSFER AND VALIDATION OF BIOANALYTICAL METHOD FOR DETECTION OF CABOTEGRAVIR IN RAT PLASMA

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY - SCIENTIFIC PROJECT FOR RSA NO. 2057 (RADER)

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY

NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB)

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY SCIENTIFIC ACTIVITIES

EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY SCIENTIFIC ACTIVITIES

CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES.

PHARMACODYNAMICS OF THE MAS-RELATED GENE X2 (MRGX2) ANTAGONIST SYR268215 IN THE HUMANIZED MRGX2 KNOCK-IN (KI) MOUSE

CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES.

PROJECT RTOR BIO-AMT-1021: DEVELOPMENT OF ANIMAL MODELS FOR EVALUATION OF MEDICAL COUNTERMEASURES FOR SARS-COV-2

CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN.

24-015894 NHLBI POPULATION SCIENCES BRANCH REQUIRES PULMONARY FUNCTION TESTING TO DETERMINE IF THE FLEXIVENT METHOD OF PULMONARY FUNCTION TESTING IS SUITABLE TO BE USED IN A LARGER STUDY.

EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.

RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP])

KICK-OFF MEETING FOR THE PHARMACOLOGY STUDIES AND ANIMAL MODEL DEVELOPMENT AND RELATED SERVICES FOR DRUG DEVELOPMENT IDIQ CONTRACT.

ANIMAL MANAGEMENT SOFTWARE

BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES

TRANSFER AND VALIDATION OF BIOANALYTICAL METHOD FOR DETECTION OF CABOTEGRAVIR IN RAT PLASMA

CHANGE THE COR LISTED UNDER H. CONTRACTING OFFICER'S REPRESENTATIVE AND PROGRAM OFFICE POCS.

DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD).

BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY SCIENTIFIC ACTIVITIES

EVALUATION OF DRUG EFFICACY IN A GUINEA PIG MODEL OF NEONATAL OPIOID WITHDRAWAL SYNDROME. THE PERIOD OF PERFORMANCE OF THIS TASK ORDER WAS SEPTEMBER 25, 2019 THROUGH SEPTEMBER 24, 2020. MODIFICATION P00005 IS TO DEOBLIGATE UNUSED FUNDS.

EVALUATION OF POTENTIAL RESPIRATORY STIMULANT. TO4. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025.

RESPIRATORY INTERACTION STUDIES IN RODENTS, ABILITY OF A TEST ARTICLE TO REVERSE THE RESPIRATORY DEPRESSANT EFFECTS OF OPIOIDS. TO5. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025.

NON-PERSONAL SERVICES FOR MAINTENANCE OF THE ANIMAL MONITORING SYSTEM FOR THE WALTER REED ARMY INSTITUTE OF RESEARCH.

NON-CLINICAL SAFETY ASSESSMENT OF TTHX1114 TO SUPPORT FUCHS ENDOTHELIAL CORNEAL DYSTROPHY IND APPLICATION. POP: SEPTEMBER 17, 2018 TO OCTOBER 30, 2020.

EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY - TASK AREA A: CORE ADMINISTRATIVE ACTIVITIES

CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL

TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR

EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT

EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT.

TASK ORDER 1 -TITLE: ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS

RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP])

AWARD OF FIVE-YEAR IDIQ FOR CTP- ASSESSING TOBACCO-RELATED CLINICAL OUTCOMES AND HUMAN BEHAVIORS IN TOBACCO

GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY

NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS.

EVALUATION OF AN ASO IN THE MOUSE CIGARETTE SMOKE AND INFLUENZA MODEL

INCREASE CLINICAL STUDY TIME

CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN